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ABSTRACT Fibroblast differentiation is an essen-
tial step during wound healing and fibrosis. Fibronec-
tin (FN) is a major component of the extracellular
matrix and occurs in two main forms: plasma and
cellular FN. The latter includes the alternatively
spliced domain A (EDA). Although EDA-containing
cellular fibronectin (EDA-FN) is associated with fi-
broblast differentiation, how EDA-FN promotes dif-
ferentiation is incompletely understood. In this
study, we investigate the mechanism by which
EDA-FN contributes to fibroblast differentiation with
emphasis on the characterization of the EDA-FN
receptor. We show that EDA-FN increases -SMA
expression (immunofluorescence), collagen deposi-
tion, cell contractility, and focal adhesion kinase
(FAK) activation (immunoblotting); whereas plasma
FN, a form lacking EDA, shows no effect. Primary
lung fibroblasts constitutively express 47 integrin
receptor (FACS and RT-PCR). Blocking of 47
reduces fibroblast adhesion to EDA-FN and inhibits
-SMA expression, collagen deposition, and FAK
activation induced by EDA-FN. Using recombinant
EDA-containing peptides, we demonstrate that the
EDA segment is sufficient to induce fibroblast differ-
entiation via binding to 47. EDA-FN induces
MAPK-Erk1/2 activation and inhibition of MEK1/2
attenuates EDA-FN-induced -SMA expression. Our
findings demonstrate that EDA-FN induces fibroblast
differentiation by a mechanism that involves binding
of EDA to 47 integrin followed by activation of
FAK and MAPK-associated signaling pathways.—
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Fibroblasts are responsible for the preservation of
extracellular matrix (ECM) homeostasis by maintain-
ing a balance between synthesis and degradation of
structural proteins in all the organs of the body. These
cells have the ability to alter their phenotype from
noncontractile, quiescent fibroblasts, and intermediate
“protomyofibroblasts” to “myofibroblasts”, which are
distinguished from their precursors by the expression
of -smooth muscle actin (-SMA), their highly con-
tractile capacity, and their ability to produce large
amounts of ECM proteins (1, 2). The differentiation of
fibroblasts into myofibroblasts requires the combined
action of mechanical tension, TGF-1 and EDA-con-
taining fibronectin (FN) (1–3).
FN is a 440-kDa dimeric ECM glycoprotein that
includes 3 different types of repeating segments, called
type I, type II, and type III, the latter being the most
abundant (4). The FN gene encodes 15 type III repeats,
which are constitutively expressed, plus 2 that are
alternatively spliced, the extra domain A (EDA) and B
(EDB) (5). EDA and EDB are encoded by single exons,
and their inclusion or exclusion from the FN mRNA is
determined by a highly regulated alternative splicing
mechanism (5). Two major forms of FN exist: plasma
FN (pFN), a soluble dimeric form found in plasma
secreted by hepatocytes, which lacks both EDA and
EDB segments; and cellular FN (cFN), an insoluble
cross-linked multimeric form found in ECM mainly
secreted by activated fibroblasts as soluble dimers and
contains variable proportions of EDA and/or EDB
segments (5, 6).
Increased expression of the EDA-containing isoform
of FN is found during embryogenesis, and once tissue
development is completed its expression drops to neg-
ligible levels (7, 8). The FN isoform lacking both EDA
and EDB domains is the most abundant form present in
normal adult tissues (7–9). Under certain conditions
such as wound healing or tissue fibrosis, where myofi-
broblasts are present in abundance, increased expres-
sion of EDA-containing cellular FN (EDA-FN) has been
observed (10–12). Although EDA-FN is necessary for
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myofibroblast differentiation (11, 12), the mechanism
by which it contributes to this effect still remains
unknown. Serini et al. (12) have proposed that EDA-FN
might interact with an uncharacterized cell surface
receptor on fibroblasts and possibly facilitate TGF-1-
driven signals.
Integrins are a family of heterodimeric transmem-
brane receptors that bind ECM components (13). It is
well established that both plasma and cellular FNs bind
several different integrins triggering intracellular sig-
nals, including early activation of focal adhesion kinase
(FAK), which has been associated with fibroblast differ-
entiation (14, 15). 51 integrin, considered the “clas-
sic” FN receptor, binds to the RGD motif of FN and
stimulates cell adhesion, migration, and proliferation
(16, 17). Members of the 4/9 subfamily of integrins
include 41,91, and 47 (16, 18). 41 and 91 are
expressed by fibroblasts (19, 20) and are known to bind
the EDA segment of FN (21). In contrast, expression of
47 integrin has not been reported in fibroblasts. In
the present study, we show that lung fibroblasts consti-
tutively express 47 integrin and provide evidence that
EDA-FN stimulates fibroblast differentiation via bind-
ing of the EDA segment to 47 integrin followed by
activation of downstream cell differentiation-linked sig-
naling pathways.
MATERIALS AND METHODS
Antibodies and reagents
Anti-EDA-FN (3E2) and anti--smooth muscle actin (-SMA)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Anti-47 integrin (DATK32), FITC-conjugated anti-E integrin
(2E7), and anti-EDA-FN (IST-9) were purchased from Abcam
(Cambridge, UK). Anti-51 integrin (BMA5), anti-91
integrin (Y9A2), and irrelevant isotype-matched IgG anti-
bodies were purchased from Chemicon (Billerica, MA,
USA). LEAF purified anti-7 integrin (FIB27) was pur-
chased from BioLegend (San Diego, CA, USA). Functional
grade purified anti-1 integrin (HMb1-1) was purchased
from eBioscience (San Diego, CA, USA). Anti-41 integrin
(PS/2) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Anti-phospho-FAK (Tyr397), anti-
FAK, anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/
Tyr204) (197G2), and anti-p44/42 MAPK (Erk1/2)
(137F5) antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA). Cy5-conjugated goat
anti-mouse and HRP-conjugated goat anti-rabbit were pur-
chased from Jackson Laboratories Inc (West Grove, PA,
USA). EDA-FN was purchased from Sigma-Aldrich or iso-
lated from media of cultured fibroblasts (11). pFN was
purchased from Innovative Research (Novi, MI). MEK
inhibitors U0126 and PD98059 were purchased from Cell
Signaling Technology.
Fibroblast isolation and culture
C57Bl/6 mice were purchased from Harlan Laboratories Ltd
(Jerusalem, Israel), and lung fibroblasts were extracted as de-
scribed previously (22). The Hebrew University-Hadassah Med-
ical School Animal Ethics Committee approved all animal
protocols. Human lung fibroblasts were obtained from lung
biopsies of patients undergoing thoracic surgery, and cells were
maintained in DME with 10% FCS, glutamine, penicillin, and
streptomycin. Informed consent was obtained. Cells between
passages 2 and 4 were used for all experiments (n3–4).
Production of EDA-containing and EDA-lacking
recombinant peptides
FN sequences containing or lacking the EDA segment were
generated from full-length cFN and full-length pFN cDNAs,
respectively. PCR amplifications were performed using the fol-
lowing primers: forward, 5-ACCATCACTGTGTATGCTGT-
CACT-3; reverse, 5-AAGTCCTGATACAACCACGGA-3. These
primers covered a sequence from base 4822 to base 5626
(numbers are as in the full-length cDNA sequence found at
GeneBank) and generated two products: one of 804 bp contain-
ing the EDA segment flanked by the 11th and 12th type III
repeats, and one of 534 bp lacking the EDA domain. PCR-
amplified fragments were then cloned in the BamHI site of the
pProEX Htb expression vector (Invitrogen Corp, San Diego,
CA, USA). Competent BL21 cells were transfected, and expres-
sion of the peptide was induced by addition of isopropyl--d-
thiogalactoside to a final concentration of 1 mM. Cells were then
lysed and disrupted by freezing/thawing and sonication. Protein
extracts were loaded on a 12% SDS-PAGE gel. Bands corre-
sponding to the EDA-containing and EDA-lacking peptides were
detected by staining the gel with 1 M KCl, cut out from the gel
and electroeluted in 50 mM carbonate-bicarbonate buffer, pH
9.6. Only the purified EDA-containing recombinant peptide
showed positive immunological reactivity to the anti-EDA mono-
clonal antibody 3E2.
Immunofluorescence
Fibroblasts (104 cells/well) were cultured on coverslips placed in
24-well plates and treated with EDA-FN, pFN, EDA-containing
peptides, or peptides lacking the EDA segment (10 g/ml, 48 h,
37°C). Cells were then fixed in 75% methanol, permeabilized in
0.2% Triton 100, blocked in 1% BSA, and incubated with
anti--SMA. Binding was detected using Cy5-conjugated goat
anti-mouse antibody. Nuclei were counterstained with pro-
pidium iodide (Sigma). Slides were examined using a Fluo-
View FV 300 confocal laser scanning biological microscope
(Olympus Corporation, Center Valley, PA, USA). Ten
fields were examined per slide. Quantification was assessed
using Image-Pro Plus 6.0 (Media Cybernetics Inc., Silver
Spring, MD, USA) on images acquired at 600 and ex-
pressed as integrated optical density (IOD) as described
previously (22). For blocking experiments, cells were preincu-
bated (10–20 g/ml, 45 min, 37°C) with anti-47 integrin
(DATK32), anti-51 integrin (BMA5), anti-7 integrin (FIB27),
anti-1 integrin (HMb1–1), irrelevant isotype-matched IgG,
MEK1/2 inhibitor U0126 (10 M, 1 h, 37°C), MEK1 inhibitor
PD98059 (20M, 1 h, 37°C) or anti-EDA (IST-9; 25g/ml, 45 min,
37°C).
To determine whether the 47 integrin is expressed by
fibroblasts in vivo, immunostaining was performed on 4–6
m paraffined lung tissue sections from mice exposed to
ovalbumin (22). After deparaffinization, slides were incu-
bated with anti-47 integrin together with anti--SMA as a
marker for myofibroblasts. Binding was detected using Cy5
anti-mouse or FITC anti-rat antibodies. Tissue slides were
examined using a FluoView FV 300 confocal laser scanning
biological microscope.
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Collagen deposition by fibroblast monolayers
Fibroblasts (5104 cells/well) were seeded in 24-well plates, and
collagen deposition was determined using the Sircol colorimet-
ric assay (Biocolor, Belfast, UK), as described previously (22), in
the presence or absence of EDA-containing cFN, pFN, EDA-
containing peptides, or peptides lacking the EDA segment (10
g/ml). Collagen deposition was expressed as fold increase
relative to deposition by untreated cells. For blocking experi-
ments, cells were preincubated with anti-47 integrin
(DATK32) (10 g/ml, 45 min, 37°C) or anti-EDA (IST-9) (25
g/ml, 45 min, 37°C).
Collagen gel contraction assay
Three-dimensional gel contraction was performed in colla-
gen matrices as described previously (23). After 24 h at 37°C,
gels were photographed and their size was determined using
ImageJ (National Institutes of Health, Bethesda, MD, USA).
Results were expressed as percentage of initial gel area.
ELISA for TGF-1
ELISA for TGF-1 was performed on cell culture medium
using a commercial kit (R&D Systems, Minneapolis, MN,
USA).
Fibroblast adhesion assay
Flat-bottom 96-well plates (BD Biosciences, San Jose, CA, USA)
were coated with EDA-FN (20 g/ml, 1 h, 37°C). Plates were
then blocked with 1% BSA (30 min, 37°C). Fibroblasts (5103
cells/well) were seeded into individual wells. Plated cells were
centrifuged to ensure equal dispersion and were incubated for
20 min (37°C, 5% CO2). Nonadherent cells were removed by
centrifuging the plate upside-down for 5 min at 500 RPM.
Adherent cells were fixed and stained with 0.5% crystal violet,
1% formaldehyde, 20% methanol followed by destaining with
PBS. Relative adherence was determined by reading the plate at
550 nm in an EL808 Ultra Microplate Reader (Bio-Tek Instru-
ments, Winooski, VT, USA). For the indicated conditions,
fibroblasts in suspension were preincubated with function-
blocking antibodies (20 g/ml, 30 min) on ice prior to plating.
RT-PCR for 7 integrin
Cellular RNA was isolated using TriReagent (Sigma). RT-PCR was
performed using standard conditions (30 cycles) (Promega, Madi-
son, WI, USA). cDNAs from murine lung fibroblasts and spleen-
derived lymphoid cells were amplified using the following primers:
forward, 5-CCTACGACTCTGGGCTCTTG-3; reverse, 5-
ACAGGTCAGCCTCAGAGCAT-3.
cDNAs from human lung fibroblasts and blood-derived T
lymphocytes were amplified using the following primers:
forward, 5-ACCGTGACCCTTGAACACTC-3; reverse, 5-TG-
CAACTCCACAATCAGCTC-3.
PCR products (194 bp for murine cells and 239 bp for
human cells) were visualized by ethidium bromide-stained
agarose gel electrophoresis. A glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA was used as control. Some
cells were exposed to 5 ng/ml of TGF-1.
Flow cytometry
Cells were incubated with phycoerythrin-conjugated anti-47
integrin (DATK32); FITC-conjugated anti-E integrin (2E7)
or irrelevant isotype-matched IgG for 30 min at room tem-
perature. Fluorescence was analyzed using a FACStar analyzer
(Becton Dickinson, Franklin Lakes, NJ, USA). Data were
processed with the CellQuest software (BD Biosciences, San
Jose, CA, USA).
Western blotting
Samples were prepared from cells grown in 6-well plates by
addition of Nonidet P-40 lysis buffer supplemented with
protease inhibitor cocktail (Pierce, Rockford, IL, USA),
sodium vanadate (Sigma), and PMSF (Sigma). Protein
concentrations were determined using the Bradford assay
(Bio-Rad, Hercules, CA, USA). Lysates were then separated
by 9% SDS-PAGE and samples were transferred to nitrocel-
lulose membranes (Bio-Rad). Membranes were blocked
with 5% dry milk in TBS/Tween-20 (TBS-T) and incubated
with anti-phospho-FAK, anti-FAK, anti-phospho-Erk1/2,
and anti-Erk1/2 antibodies. Membranes were incubated
with HRP-conjugated anti-rabbit IgG, and blots were devel-
oped with the SuperSignal West Pico Chemiluminiscent
Substrate kit (Thermo Scientific, Rockford, IL, USA) and
exposed to Fuji Medical X-Ray films (FujiFilm Corp.,
Tokyo, Japan). Image analysis was performed using ImageJ
(U.S. National Institutes of Health, Bethesda, MD, USA).
Data analysis
The mean  se values are given for each group. One-way
analysis of variance (ANOVA) followed by Bonferroni posttest
was performed to compare groups. Values of P  0.05 were
considered statistically significant.
RESULTS
EDA-FN induces fibroblast differentiation
We first compared the effects of EDA-FN and the non-EDA-
containing form pFN on fibroblasts isolated from lungs of
C57Bl/6 mice and evaluated different aspect of fibroblast
differentiation, namely -SMA expression, collagen produc-
tion, collagen gel contractility, and TGF-1 release.
Expression of -SMA was assessed by quantitative
immunofluorescence (22). EDA-FN (10 g/ml, 48 h)
increased -SMA expression in comparison with un-
treated cells and pFN (Fig. 1A, P0.001). pFN (10
g/ml, 48 h) did not induce changes in -SMA expres-
sion levels in comparison with untreated cells (Fig. 1A).
Preincubation with anti-EDA antibody (IST-9) inhib-
ited EDA-FN-induced -SMA expression (Fig. 1A;
P0.001).
Fibroblast collagen deposition was measured by the
Sircol colorimetric assay (22). EDA-FN (10 g/ml,
48 h) increased fibroblast collagen deposition, whereas
pFN (10 g/ml, 48 h) showed minimal effect on
collagen deposition (Fig. 1B; 282% for EDA-FN vs.
53% for pFN over untreated cells, P0.01). Preincu-
bation with anti-EDA antibody (IST-9) inhibited EDA-
FN-induced collagen deposition (Fig. 1B; P0.01).
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Fibroblast contractility was determined by the colla-
gen gel contraction assay (23). After 24 h, untreated
cells reduced the gel to 64% of its initial size at time 0
(Fig. 1C). EDA-FN (10 g/ml, 24 h) reduced the size of
the gel by an additional 20% in comparison with
untreated cells (Fig. 1C, P0.01), whereas pFN (10
g/ml, 24 h) reduced the gel by only an additional 8%
as compared to untreated cells.
TGF-1 secretion into culture medium by lung fibro-
blasts was determined by ELISA. While EDA-FN in-
creased TGF-1 release by 2-fold in comparison with
untreated cells (Fig. 1D, P0.01), exposure to pFN did
not affect TGF-1 release. Pretreatment with anti-EDA
antibody (IST-9) inhibited EDA-FN-induced TGF-1
release (Fig. 1D, P0.01).
47 integrin is constitutively expressed in lung
fibroblasts and mediates fibroblast adhesion to
EDA-FN
The effect exhibited by EDA-FN on fibroblast differen-
tiation suggests the existence of a cell surface receptor
that mediates this process. In an attempt to identify
such a receptor, we first determined fibroblast adhe-
sion to EDA-FN in the presence of blocking antibod-
ies (20 g/ml) for integrins 41, 91, and 47.
Blocking of integrin 47 inhibited the adhesion of
fibroblast to EDA-FN (Fig. 2A; P0.05). In addition,
blocking of 41, an integrin receptor expressed by
fibroblasts (19), which is known to bind the EDA
segment (21), also abrogated cell adhesion to EDA-
FN, whereas blocking of integrin 91 showed no
effect (Fig. 2A; P0.01).
The 4 subunit is known to be expressed on fibro-
blasts as part of the 41 complex (15, 19). In contrast,
the 7 subunit has not previously been identified on
fibroblasts. We then evaluated the expression of both
the 7 subunit and the 47 integrin complex in lung
fibroblasts by RT-PCR and flow cytometry. Primary
murine lung fibroblasts constitutively expressed 7 in-
tegrin mRNA (Fig. 2B, lane 1). Addition of TGF-1 (5
ng/ml, 48 h) did not increase 7 integrin mRNA levels
(Fig. 2B, lane 2). Primary human lung fibroblasts also
expressed the 7 integrin subunit (Fig. 2C). FACS
analysis demonstrated expression of the 47 complex
in murine lung fibroblasts (mean fluorescence inten-
sity 	 fold over control  12.80.7) (Fig. 2D). We did
not observe positive staining for the E subunit, which
also forms a complex with the 7 subunit (13) (data not
shown). We also observed positive immunostaining for
47 integrin in vivo in myofibroblasts from lung tissue
of OVA-treated mice (Fig. 2E).
Blocking of 47 integrin inhibits EDA-FN-induced
myofibroblast differentiation
To investigate whether 47 mediates EDA-FN-induced
fibroblast differentiation, cells were preincubated with
anti-47 blocking antibodies in the presence or ab-
sence of EDA-FN and -SMA expression, collagen pro-
duction and TGF-1 release were determined. Blocking
of 47 inhibited EDA-FN-induced -SMA expression
(P0.001; Fig. 3A). Preincubation with anti-51 block-
ing antibodies did not exert inhibitory effects on fibro-
blast differentiation. Fibroblasts were also preincu-
bated with blocking antibodies against the 7 and 1
subunits. While pretreatment with anti-7 integrin
antibodies completely inhibited the induction of
-SMA expression observed after exposure to 10
Figure 1. EDA-FN induces
markers of fibroblast differenti-
ation. Primary lung fibroblasts
were exposed to 10 g/ml
EDA-FN or non-EDA-contain-
ing pFN), and markers of fibro-
blast differentiation were evalu-
ated as described in Materials
and Methods. EDA-FN in-
duced expression of -SMA
(A), ***P 0.001 vs. untreated
cells and pFN; collagen deposi-
tion (B), **P  0.01 vs. pFN;
cell contractility (C), *P  0.05
vs. pFN, **P  0.01 vs. un-
treated cells; and TGF-1 re-
lease (D), **P  0.01 vs. un-
treated cells and pFN. Prein-
cubation with anti-EDA mono-
clonal antibody IST-9 inhibited
the effects induced by EDA-FN.
Experiments were performed 3
times; means  se are shown.
Scale bars 10 m (A); 1 cm (C).
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g/ml EDA-FN (Fig. 3A; P0.001); anti-1 integrin
antibodies did not alter EDA-FN-induced -SMA ex-
pression. The absence of effect with anti-1 antibod-
ies rules out a role for 1-containing integrins such as
41 and 91 on fibroblast differentiation. Pretreat-
ment with anti 47 integrin blocking antibodies also
reduced EDA-FN-induced collagen production (Fig.
3B) and EDA-FN-induced TGF-1 release (Fig. 3C) to
levels similar to those observed for untreated cells
(internal control) (315% over control without anti-
47 vs. 74% over control with anti-47 for colla-
gen production, P0.001; 1.040.06 ng/ml without
anti-47 vs. 0.630.05% ng/ml with anti-47 for
TGF-1 release, P0.001).
The EDA segment is sufficient to induce a
myofibroblast phenotype through binding to 47
integrin
To determine whether the ability of EDA-FN to induce
fibroblast differentiation is attributable to the EDA
segment and—if so—due to direct binding of the EDA
segment to 47, we generated recombinant fragments
of FN containing or lacking the EDA segment. Recom-
binant peptides (10 g/ml) containing the EDA seg-
ment (EDA
 peptides) increased -SMA expression
(Fig. 4A; P0.001 vs. untreated cells) and collagen
production by 26  2% (Fig. 4B; P0.01 vs. untreated
cells). The effect observed for the EDA
 peptides was
similar to that observed for EDA-FN. Recombinant
peptides lacking the EDA segment (EDA	 peptides)
were used as control and showed no effect.
To determine whether the effect of the EDA segment
is via binding to 47 integrin, we evaluated the expres-
sion of -SMA after exposure to EDA
 peptides in the
presence or absence of anti 47 blocking antibodies.
We observed that preincubation with anti-47 antibod-
ies completely abrogated the increased expression of
-SMA that was induced by 10 g/ml EDA
 peptides
(Fig. 4C; P0.01).
EDA-FN enhances FAK activation via integrin 47
Binding of different sequences of FN to integrin recep-
tors is known to activate FAK via phosphorylation of
tyrosine residues (24, 25). The ratio between phosphor-
ylated FAK and total FAK was determined by quantita-
tive immunoblotting. EDA-FN (10 g/ml) induced
phosphorylation of the tyrosine 397 of FAK on lung
fibroblasts in a time-dependent manner, with a maxi-
mal effect observed after 6 h of incubation (3.1-fold
over untreated cells) (Fig. 5A). We also compared FAK
activation between EDA-FN and pFN and observed that
cells exposed to 10 g/ml EDA-FN significantly in-
creased the phosphorylated FAK:FAK ratio in compar-
ison to 10 g/ml pFN (Fig. 5B; 1.040.08 for EDA-FN
Figure 2. 47 integrin is constitutively expressed in lung fibroblasts and mediates adhesion to EDA-FN. A) Lung fibroblasts were
preincubated with blocking antibodies and seeded in 96-well plates previously coated with EDA-FN to determine cell adhesion.
Blocking of 47 and 41 integrins inhibited fibroblast adhesion to EDA-FN. *P  0.05, **P0.01 vs. untreated cells).
Experiments were performed 3 times; means  se are shown. B) mRNA expression of 7 was evaluated by RT-PCR in murine
primary lung fibroblasts (lane 1). Addition of 5 ng/ml TGF-1 to lung fibroblasts did not alter 7 mRNA expression (lane 2).
Murine lymphoid cells (lane 3) were used as a positive control. C) mRNA expression of 7 in human primary lung fibroblasts
(lane 1) and in human T lymphocytes (lane 3, positive control). No band was observed in the absence of cDNA (lane 2, negative
control). D) Staining for 47 integrin (black histograms) and irrelevant IgG isotype control (gray histograms) was evaluated
by flow cytometry on murine primary lung fibroblasts and lymphoid cells (positive control). E) Expression of 47 integrin
(green, left panel), -SMA (red, middle panel), and colocalization (yellow, right panel) was evaluated in murine lung tissue by
immunostaining (white arrows). Scale bar  10 m. Experiments were repeated 3 times; representative images are shown.
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vs. 0.590.07 for pFN; P0.01). To determine whether
the EDA segment can induce FAK activation, the phos-
phorylated FAK:FAK ratio was assessed in fibroblasts
exposed to EDA
 peptides or EDA	 peptides. Expo-
sure of cells to 10 g/ml EDA
 peptides for 3 h
increased phosphorylated FAK:FAK ratio in compari-
son with cells treated with 10 g/ml EDA	 peptides
(Fig. 5C). No differences were detected between cells
treated with EDA	 peptides and untreated cells. To
evaluate whether EDA-FN activates FAK via 47 inte-
Figure 3. EDA-FN induces myofibroblast differentiation via 47 integrin. Fibroblasts were exposed to 10 g/ml EDA-FN in the
presence of blocking antibodies for 47, 51, 7, or 1 integrins and expression of -SMA was assessed by immunofluores-
cence, quantified and expressed as integrated optical density (IOD). Experiments were performed 4 times; representative
images are shown. A) Preincubation with anti-47 or anti-7 blocking antibodies (45 min, 37°C) inhibited EDA-FN-induced
-SMA expression in fibroblasts. Scale bar  20 m. B, C) EDA-FN-induced collagen deposition, assessed by the Sircol assay (B)
and EDA-FN-induced TGF-1 release, determined by ELISA (C), were abrogated in fibroblasts preincubated with anti-47
blocking antibodies. ***P  0.001.
Figure 4. The EDA segment of EDA-FN is sufficient to induce
myofibroblast differentiation via 47 integrin. To test the contribu-
tion of the EDA segment to fibroblast differentiation, cells were
exposed to 10 g/ml of recombinant peptides containing (EDA
) or
lacking (EDA	) the EDA segment (see Materials and Methods). A, B)
EDA
 peptides increased expression of -SMA (A) and collagen deposition (B) in a manner similar to EDA-FN. No effect
was observed after treatment with EDA	 peptides used as control. C) Exposure to anti-47 integrin blocking antibodies
abrogated the effect observed for EDA
 peptides on -SMA expression. Scale bar  10 m. **P  0.01, ***P  0.001.
Experiments were performed 3 times; representative images are shown.
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grin, cells were exposed to 10 g/ml EDA-FN in the
presence or absence of anti-47 integrin antibodies
(preincubation for 45 min at 37°C). As shown in Fig.
5D, blocking of 47 integrin decreased phosphory-
lated FAK:FAK ratio induced by EDA-FN to levels
similar to untreated cells (0.750.09 in the presence of
anti-47 integrin vs. 1.240.11 in the absence of
anti-47 integrin; P0.01).
EDA-FN-mediated fibroblast differentiation is MAP
kinase Erk1/2 dependent
The intracellular signals involved in EDA-FN-
mediated fibroblast differentiation are virtually un-
known. We explored whether the p44/42 MAP kinase
(ERK 1/2) signaling pathway, which is key in cell
differentiation, proliferation and motility (26), con-
tributes to fibroblast differentiation. Exposure to 10
g/ml EDA-FN and EDA-containing peptides en-
hanced phosphorylation of p44/42 MAPK (Erk1/2)
in lung fibroblasts in a time-dependent manner with
maximal effect observed after 3 h of incubation
(3.7-fold over untreated cells) (Fig. 6A). Pretreat-
ment (1 h, 37°C) with 10 g/ml of MEK1/2 inhibitor
U0126 or 20 g/ml of MEK1 inhibitor PD98059
inhibited EDA-FN-induced -SMA expression in fi-
broblasts (Fig. 6B; P0.001 for U0126 and P0.01
for PD98059 vs. EDA-FN). U0126 showed higher
inhibitory capacity (96% inhibition) in comparison
with PD98059 (62% inhibition).
DISCUSSION
Fibroblast differentiation to a myofibroblast phenotype
is an essential step in the process of fibrogenesis (1, 2).
Although a link between EDA-FN and fibroblast differ-
entiation has been known for more than 15 yr (10), the
mechanism by which this interaction occurs has not
been fully elucidated. In the present study, we show
that 47 integrin is constitutively expressed on lung
fibroblasts and provide evidence that EDA-FN induces
fibroblast differentiation through binding of the EDA
segment to 47 integrin receptor and activation of
FAK and MAP kinase Erk1/2.
Previous studies have reported that EDA-FN is more
potent than the EDA-lacking form pFN in promoting
fibroblast adhesion, migration, and proliferation (27,
28). EDA-FN also induces the expression of -SMA in
lipocytes more efficiently than pFN, resulting in the
differentiation of these cells into myofibroblast-like
cells (10). In this study we show that EDA-FN, but not
pFN, induces -SMA expression, collagen production,
gel contractility, and TGF-1 release on primary lung
fibroblasts. These effects are blocked by the anti-EDA
monoclonal antibody (IST-9), thus adding further evi-
dence for a role of the EDA segment of cFN on
fibroblast differentiation.
Although ours and several other studies suggest the
presence of a specific cell surface receptor that binds
EDA to mediate the effect of EDA-FN on fibroblast
differentiation (2, 10, 12, 29), no such receptor has
been identified to date. In this study we demonstrate
that 47 integrin is constitutively expressed in murine
and human lung fibroblasts and that cell adhesion to
EDA-FN is partially mediated by this receptor. Expres-
sion of the 47 integrin has previously been reported
in human and murine eosinophils, basophils, NK cells,
CD4
 T, B lymphocytes and endothelial cells (30–32).
This integrin plays a role in cell adhesion, rolling,
differentiation, and survival of eosinophils and lympho-
Figure 5. EDA-FN activates FAK
via 47 integrin receptor. Cell
lysates obtained from fibroblasts
exposed to EDA-FN, non EDA-
containing pFN, EDA-contain-
ing peptides (EDA
) or EDA-
lacking peptides (EDA	) were
separated by SDS-PAGE and
subjected to immunoblotting
with anti-phospho-FAK and an-
ti-FAK antibodies. Densitomet-
ric analysis calculated as ratio of
phospho-FAK to total FAK was
then assessed. A) Time course
of FAK activation by EDA-FN
showed a maximum effect after
3–6 h of incubation. B) Expo-
sure to EDA-FN increased FAK
activation in comparison with
pFN. **P  0.01 vs. pFN;
***P 0.001 vs. untreated cells.
C) Lysates from cells treated
with EDA
 peptides showed
greater FAK activation than ly-
sates treated with EDA	 pep-
tides. D) Blocking of 47 inte-
grin reduced EDA-FN-induced
FAK activation. **P  0.01. Blots shown are representative of 2 or 3 independent experiments from different lysates.
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cytes (30–34). 7-deficient mice have impaired recruit-
ment of lymphocytes, mast cell progenitors and eosin-
ophils to the gastrointestinal tract (35). We did not
observe the expression of the E subunit, which has also
been shown to form complexes with 7 (13, 30).
Cytokines and growth factors are likely to regulate the
expression of 47. While tumor necrosis factor  and
interleukin (IL)-1  increase 7 expression in endothe-
lial cells (32), IL-5 and platelet-activating factor (PAF)
do not affect 47 expression on eosinophils (34, 35).
Addition of TGF-1 increases the expression of 4
subunit on lung fibroblasts (15); however, we found
that it does not alter the expression of the 7 subunit in
lung fibroblasts.
We found that EDA-FN induces lung fibroblast dif-
ferentiation via 47 integrin, since blocking of this
integrin attenuates this effect. Furthermore, using 7
blocking antibodies, we demonstrated that the 7 sub-
unit is essential for the stimulatory effect of EDA-FN.
47 integrin binding sites have been previously iden-
tified in minimal sequences that share the dipeptide
DV present on the CS-1 segment of the IIICS region
(36, 37) and in the KLDAPT sequence present on the
III5 repeat (38) of all forms of FN. A previous study has
reported that EDA-FN increases eosinophil survival
through 47 integrin and these authors hypothesize
that this effect is mediated by the 47 integrin binding
site on the CS-1 peptide (33). Our findings clearly
demonstrate that fibroblast differentiation is not medi-
ated via the 47 binding site present on the IIICS or
the III5 regions as pFN does not induce differentiation.
In the present study, we provide evidence for the
existence of another binding site for 47 located on
the EDA-segment; however, the amino acid sequence
that binds 47 integrin has not yet been identified. It
has been shown that the EDGIHEL sequence included
in the EDA segment binds 41 and 91 integrins
(21). The EDA domain includes DV segments (ref. 39,
GenBank accession number AF 095690) and it is pos-
sible that 47 binds to EDA via DV-containing se-
quences. Further studies are necessary to address this
issue.
It has been proposed that the EDA segment might
not induce fibroblast differentiation directly, but rather
its insertion into the FN molecule brings about a
conformational change thereby increasing the accessi-
bility of the RGD binding site to 51 (27) or exposing
other integrin binding sites present on FN. Our study
demonstrates that this is unlikely to be the case for
fibroblast differentiation. This is supported by three
lines of evidence: EDA-FN-induced -SMA expression is
not affected by the addition of blocking antibodies
against 51 and 1 integrins; recombinant EDA-con-
taining peptides are sufficient to induce fibroblast
differentiation; and the addition of anti-47 blocking
antibodies inhibits recombinant EDA-containing pep-
tides-induced -SMA expression. Thus, taken together,
these findings strongly suggest that the EDA segment
itself binds to 47 integrin and thereby induces a
myofibroblast phenotype. Our results are consistent
with previous studies showing that antibodies against
EDA (clone IST-9) inhibit fibroblast differentiation and
that addition of a recombinant EDA segment promotes
3T3 cell adhesion (10, 12, 29). Jarnagin et al. (10)
found that recombinant EDA-containing peptides in-
creased -SMA expression in lipocytes; while Serini et
Figure 6. MAP kinase Erk1/2 activation by EDA-FN is required for fibroblast
differentiation. Cell lysates obtained from fibroblasts exposed to 10 g/ml
EDA-FN or EDA-containing peptides were separated by SDS-PAGE and
subjected to immunoblotting with anti-phospho-p44/42 MAPK (Erk1/2)
and anti-p44/42 MAPK (Erk1/2) antibodies. A) EDA-FN activates Erk1/2,
showing maximum effect after 3 h of incubation. B) Lysates from cells treated with EDA
 peptides showed greater
Erk1/2 activation than lysates treated with EDA	 peptides. Blots shown are representative of 2 experiments from
different lysates. C) Fibroblasts were preincubated (1 h, 37°C) with MEK inhibitors U0126 (10 g/ml) and PD98059
(20 g/ml) and then exposed to 10 g/ml EDA-FN for 48 h. Cell expression of -SMA in response to EDA-FN was
totally inhibited by U0126 and partially inhibited by PD98059, as assessed by immunofluorescence. **P  0.01;
***P  0.001. Experiments were performed 3 times; data are presented as means  se.
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al. (12) showed inhibitory effects for recombinant EDA
fragments on -SMA expression in skin fibroblasts.
These discrepancies may be due to the different struc-
ture of the peptides used.
The intracellular signal transduction pathways trig-
gered following the binding of EDA-FN to integrin
receptors have yet not been elucidated. Binding of
different isoforms of FN to integrins activates focal
adhesion kinase (FAK) (24), an early mediator of
integrin-linked intracellular signals (25). FAK activa-
tion has been previously associated with fibroblast
differentiation (14, 15). We show in this study that the
EDA segment triggers FAK activation following binding
to 47 integrin. Interestingly, Thannickal et al. (15)
found that induction of myofibroblast differentiation
via TGF-1 requires integrin-dependent FAK activation
and they suggest that this effect may be through
induction of integrin receptors and/or enhanced FN
expression in response to TGF-1. Mitogen-activated
protein kinase (MAPK) Erk1/2 is involved in cell
differentiation (26). We found that EDA-FN and EDA-
containing peptides activate MAPK Erk1/2 in primary
fibroblasts. Blocking of MAPK Erk1/2 by biochemical
inhibitors of MAPK kinase MEK1 and MEK2 abrogated
EDA-FN-induced -SMA expression. Activation of Erk2
by EDA-FN has also been observed in CHO cells but, in
contrast to our findings, in this study, Erk2 activation
was observed in the absence of FAK (28). Our results,
therefore, demonstrate that activation of MAPK Erk1/2
is essential for fibroblast differentiation and is mediated
by the EDA segment of FN.
In summary, we demonstrate that EDA-FN contributes
to fibroblast differentiation through binding of the EDA
segment to 47 integrin and activation of the intracellu-
lar signal transduction proteins FAK and MAP kinase
Erk1/2. Our study advances present understanding of the
mechanism by which EDA-FN mediates fibroblast differ-
entiation and fibrogenesis. How EDA-FN interacts with
TGF-1 and/or mechanical tension to induce fibroblast
differentiation requires further investigation.
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